NEW YORK (GenomeWeb News) – Proteome Sciences today announced a conditional placement of nearly 17.9 million new ordinary shares in order to raise £5 million ($8.3 million).

The UK-based firm said it has conditionally placed the shares of ₤.01 each to raise the funds with new and existing investors at ₤.28 per share. Proteome Sciences Chief Executive Christopher Pearce has subscribed for about 3.6 million shares at the placing price, and following the transaction he will hold 35.1 million, or a little more than 16 percent, of the firm's enlarged share capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.